Cargando…

Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment

Adult T-cell leukaemia/lymphoma (ATLL) is an aggressive malignancy of mature activated T cells caused by human T-cell lymphotropic virus type I (HTLV-1). Prognosis is severe because of intrinsic chemoresistance and severe immuosuppression. Four different subtypes are described with different outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Marçais, Ambroise, Suarez, Felipe, Sibon, David, Bazarbachi, Ali, Hermine, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504218/
https://www.ncbi.nlm.nih.gov/pubmed/23213552
http://dx.doi.org/10.1155/2012/932175
_version_ 1782250590693228544
author Marçais, Ambroise
Suarez, Felipe
Sibon, David
Bazarbachi, Ali
Hermine, Olivier
author_facet Marçais, Ambroise
Suarez, Felipe
Sibon, David
Bazarbachi, Ali
Hermine, Olivier
author_sort Marçais, Ambroise
collection PubMed
description Adult T-cell leukaemia/lymphoma (ATLL) is an aggressive malignancy of mature activated T cells caused by human T-cell lymphotropic virus type I (HTLV-1). Prognosis is severe because of intrinsic chemoresistance and severe immuosuppression. Four different subtypes are described with different outcomes, and treatment strategies vary according to the different clinical courses. Japanese trials show that combinations of chemotherapy can increase the response rates especially in the lymphoma subtype. However, patients have a high rate of relapse and the outcome remains extremely poor. Recently, a worldwide meta-analysis demonstrated that the combination of Zidovudine and Interferon-alpha (IFN) is effective in the leukemic subtypes (smoldering, chronic, and acute) and influences favorably the course of the disease. In order to prevent relapse, clinical trials testing new drugs such as monoclonal antibodies or combinations such as arsenic/IFN are needed. Finally, allogeneic stem cell transplantation is a feasible option but bears a very high rate of complications.
format Online
Article
Text
id pubmed-3504218
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-35042182012-12-04 Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment Marçais, Ambroise Suarez, Felipe Sibon, David Bazarbachi, Ali Hermine, Olivier Leuk Res Treatment Review Article Adult T-cell leukaemia/lymphoma (ATLL) is an aggressive malignancy of mature activated T cells caused by human T-cell lymphotropic virus type I (HTLV-1). Prognosis is severe because of intrinsic chemoresistance and severe immuosuppression. Four different subtypes are described with different outcomes, and treatment strategies vary according to the different clinical courses. Japanese trials show that combinations of chemotherapy can increase the response rates especially in the lymphoma subtype. However, patients have a high rate of relapse and the outcome remains extremely poor. Recently, a worldwide meta-analysis demonstrated that the combination of Zidovudine and Interferon-alpha (IFN) is effective in the leukemic subtypes (smoldering, chronic, and acute) and influences favorably the course of the disease. In order to prevent relapse, clinical trials testing new drugs such as monoclonal antibodies or combinations such as arsenic/IFN are needed. Finally, allogeneic stem cell transplantation is a feasible option but bears a very high rate of complications. Hindawi Publishing Corporation 2012 2012-02-14 /pmc/articles/PMC3504218/ /pubmed/23213552 http://dx.doi.org/10.1155/2012/932175 Text en Copyright © 2012 Ambroise Marçais et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Marçais, Ambroise
Suarez, Felipe
Sibon, David
Bazarbachi, Ali
Hermine, Olivier
Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment
title Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment
title_full Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment
title_fullStr Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment
title_full_unstemmed Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment
title_short Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment
title_sort clinical trials of adult t-cell leukaemia/lymphoma treatment
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504218/
https://www.ncbi.nlm.nih.gov/pubmed/23213552
http://dx.doi.org/10.1155/2012/932175
work_keys_str_mv AT marcaisambroise clinicaltrialsofadulttcellleukaemialymphomatreatment
AT suarezfelipe clinicaltrialsofadulttcellleukaemialymphomatreatment
AT sibondavid clinicaltrialsofadulttcellleukaemialymphomatreatment
AT bazarbachiali clinicaltrialsofadulttcellleukaemialymphomatreatment
AT hermineolivier clinicaltrialsofadulttcellleukaemialymphomatreatment